1-8 of 8
Stéphane de Botton
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Venetoclax-Proteasome inhibitor-Dexamethasone for unfit patients with Blastic Plasmacytoid Dendritic Cell Neoplasm

Sabine Khalife-Hachem, Arnaud Pages, Elie Akoury, Sarah Bonnet, Rudy Birsen, Clemence Busquet, Adrien Contejean, Alina Danu, Stéphane De Botton, Marie De Charette, Pierre-Yves Dumas, Arnaud Jaccard, Anne Marfaing-Koka, Christophe Willekens, Eric Deconinck, David Ghez
Journal: Blood Advances
Blood Adv bloodadvances.2024014590.
https://doi.org/10.1182/bloodadvances.2024014590
Published: 2024
Journal Articles

Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome

Clinical Trials & Observations
Courtney D. DiNardo, Gail J. Roboz, Justin M. Watts, Yazan F. Madanat, Gabrielle T. Prince, Praneeth Baratam, Stéphane de Botton, Anthony Stein, James M. Foran, Martha L. Arellano, David A. Sallman, Mohammad Hossain, Dylan M. Marchione, Xiaofei Bai, Prapti A. Patel, Stephanie M. Kapsalis, Guillermo Garcia-Manero, Amir T. Fathi
Journal: Blood Advances
Blood Adv (2024) 8 (15): 4209–4220.
https://doi.org/10.1182/bloodadvances.2023012302
Published: 2024
Includes: Supplemental data
Journal Articles

Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib: pooled analysis from clinical trials

Clinical Trials & Observations
Pau Montesinos, Amir T. Fathi, Stéphane de Botton, Eytan M. Stein, Amer M. Zeidan, Yue Zhu, Thomas Prebet, Carlos E. Vigil, Iryna Bluemmert, Xin Yu, Courtney D. DiNardo
Journal: Blood Advances
Blood Adv (2024) 8 (10): 2509–2519.
https://doi.org/10.1182/bloodadvances.2023011914
Published: 2024
Includes: Supplemental data
Journal Articles

LSC17 score complements genetics and measurable residual disease in acute myeloid leukemia: an ALFA study

Clinical Trials & Observations
Loïc Vasseur, Laurène Fenwarth, Jérôme Lambert, Stéphane de Botton, Martin Figeac, Céline Villenet, Maël Heiblig, Pierre-Yves Dumas, Christian Récher, Céline Berthon, Emilie Lemasle, Delphine Lebon, Juliette Lambert, Christine Terré, Karine Celli-Lebras, Hervé Dombret, Claude Preudhomme, Meyling Cheok, Raphael Itzykson, Nicolas Duployez
Journal: Blood Advances
Blood Adv (2023) 7 (15): 4024–4034.
https://doi.org/10.1182/bloodadvances.2023010155
Published: 2023
Includes: Supplemental data
Journal Articles

Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1 -mutated AML

Clinical Trials & Observations
Stéphane de Botton, Pierre Fenaux, Karen Yee, Christian Récher, Andrew H. Wei, Pau Montesinos, David C. Taussig, Arnaud Pigneux, Thorsten Braun, Antonio Curti, Carolyn Grove, Brian A. Jonas, Asim Khwaja, Ollivier Legrand, Pierre Peterlin, Montserrat Arnan, William Blum, Daniela Cilloni, Devendra K. Hiwase, Joseph G. Jurcic, Jürgen Krauter, Xavier Thomas, Justin M. Watts, Jay Yang, Olga Polyanskaya, Julie Brevard, Jennifer Sweeney, Emma Barrett, Jorge Cortes
Journal: Blood Advances
Blood Adv (2023) 7 (13): 3117–3127.
https://doi.org/10.1182/bloodadvances.2022009411
Published: 2023
Includes: Supplemental data
Journal Articles

Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML

Clinical Trials & Observations
Stéphane de Botton, Thomas Cluzeau, Carlos Vigil, Rachel J. Cook, Philippe Rousselot, David A. Rizzieri, Jane L. Liesveld, Pierre Fenaux, Thorsten Braun, Anne Banos, Joseph G. Jurcic, Mikkael A. Sekeres, Michael R. Savona, Gail J. Roboz, Dale Bixby, Kate Madigan, Angela Volkert, Kristin Stephens, Qing Kang-Fortner, Kristen Baker, Sofia Paul, Michael McKeown, John Carulli, Matthew Eaton, Graeme Hodgson, Christopher Fiore, Michael J. Kelly, David A. Roth, Eytan M. Stein
Journal: Blood Advances
Blood Adv (2023) 7 (9): 1858–1870.
https://doi.org/10.1182/bloodadvances.2022008806
Published: 2023
Includes: Supplemental data
Journal Articles

Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results

Clinical Trials & Observations
Claude Gardin, Cécile Pautas, Elise Fournier, Raphaël Itzykson, Emilie Lemasle, Jean-Henri Bourhis, Lionel Adès, Jean-Pierre Marolleau, Jean-Valère Malfuson, Lauris Gastaud, Emmanuel Raffoux, Juliette Lambert, Thorsten Braun, Xavier Thomas, Sylvain Chantepie, Thomas Cluzeau, Stéphane de Botton, Céline Berthon, Nicolas Boissel, Nicolas Duployez, Christine Terré, Régis Peffault de Latour, Mauricette Michallet, Karine Celli-Lebras, Claude Preudhomme, Hervé Dombret
Journal: Blood Advances
Blood Adv (2020) 4 (9): 1942–1949.
https://doi.org/10.1182/bloodadvances.2019001349
Published: 2020
Includes: Supplemental data
Journal Articles

Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1 -mutant relapsed or refractory AML

Clinical Trials & Observations
Sung Choe, Hongfang Wang, Courtney D. DiNardo, Eytan M. Stein, Stéphane de Botton, Gail J. Roboz, Jessica K. Altman, Alice S. Mims, Justin M. Watts, Daniel A. Pollyea, Amir T. Fathi, Martin S. Tallman, Hagop M. Kantarjian, Richard M. Stone, Lynn Quek, Zenon Konteatis, Lenny Dang, Brandon Nicolay, Parham Nejad, Guowen Liu, Vickie Zhang, Hua Liu, Meredith Goldwasser, Wei Liu, Kevin Marks, Chris Bowden, Scott A. Biller, Eyal C. Attar, Bin Wu
Journal: Blood Advances
Blood Adv (2020) 4 (9): 1894–1905.
https://doi.org/10.1182/bloodadvances.2020001503
Published: 2020
Includes: Supplemental data